OpenResearchAlpha

Pediatric Blood & Cancer · 20 Nov 2026

Late Effects of 131 I‐MIBG in Survivors of High‐Risk Neuroblastoma: A Report From the Children's Oncology Group LEAHRN Study

Prerna Kumar, Maggie Cupit‐Link, Sara M. Federico, Jenna K. Bardwell, Steven G. DuBois, Pei‐Chi Kao, Wendy B. London, Lisa R. Diller, Tara O. Henderson

0
Citations
no database records one yet
0
Citations in 2026
so far
–
Leading author's h-index
no author has a profile yet
14
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

ABSTRACT Background Meta‐iodobenzylguanidine radiolabeled with iodine‐131 ( 131 I‐MIBG) is used to treat high‐risk neuroblastoma (HRNBL). Late toxicities of 131 I‐MIBG have not been well studied due to limited survival of patients receiving this therapy for relapsed disease. Methods The Children's Oncology Group LEAHRN study evaluated HRNBL survivors diagnosed after 2000 and alive at least 5 years from diagnosis. Clinical history and the prevalence of late effects were summarized for participants treated with 131 I‐MIBG (cases). Participants who did not receive 131 I‐MIBG were randomly selected and matched by age at diagnosis and relapse history (controls) in a 1:2 case–control study design. Chi‐squared analysis was used to evaluate the association between 131 I‐MIBG and late toxicities. Results Of 375 participants in the LEAHRN analytic cohort, 32 (8.5%) received 131 I‐MIBG. Differences in the proportion with thyroid toxicity and growth failure were observed but not statistically significant. The proportions of other major organ toxicities were not different between cases and controls, including subsequent malignancy. Discussion No statistically significant differences were identified in the burden of late toxicities for HRNBL survivors treated with and without 131 I‐MIBG. A small sample size likely limited the ability to detect statistically significant differences. Our data provide information for follow‐up care of 131 I‐MIBG‐treated survivors and clinical trial design.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (9)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (14)

What it cites, from open citation data, with Crossref's record of each.